

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH **ACUTE GOUT**

1. Badlissi F: **Gout**. In: *BMJ Best Practice*. 2020.
2. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C *et al*: **2020 American College of Rheumatology Guideline for the Management of Gout**. *Arthritis care & research* 2020, **72**(6):744-760.
3. Latourte A, Pascart T, Flipo RM, Chalès G, Coblenz-Baumann L, Cohen-Solal A, Ea HK, Grichy J, Letavernier E, Lioté F *et al*: **2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares**. *Joint Bone Spine* 2020, **87**(5):387-393.
4. Punzi L, Scanu A, Galozzi P, Luisetto R, Spinella P, Scirè CA, Oliviero F: **One year in review 2020: gout**. *Clinical and experimental rheumatology* 2020, **38**(5):807-821.
5. Richette P, Doherty M, Pascual E, Barskova V, Becce F: **2016 updated EULAR evidence-based recommendations for the management of gout**. 2017, **76**(1):29-42.
6. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM *et al*: **The British Society for Rheumatology Guideline for the Management of Gout**. *Rheumatology (Oxford, England)* 2017, **56**(7):e1-e20.
7. Qaseem A, Harris RP, Forciea MA: **Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians**. *Annals of internal medicine* 2016.
8. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merrill J, Lee S, Prakash S *et al*: **2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis**. *Arthritis care & research* 2012, **64**(10):1447-1461.
9. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H *et al*: **2016 updated EULAR evidence-based recommendations for the management of gout**. *Annals of the rheumatic diseases* 2017, **76**(1):29-42.
10. GuipClinGot: **Clinical practice guidelines for management of gout**. In.: Spanish Society of Rheumatology; 2013.
11. Pekarek B, Osher L, Buck S, Bowen M: **Intra-articular corticosteroid injections: a critical literature review with up-to-date findings**. *Foot (Edinburgh, Scotland)* 2011, **21**(2):66-70.
12. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R: **Intra-articular glucocorticoids for acute gout**. *The Cochrane database of systematic reviews* 2013(4):CD009920.
13. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F *et al*: **EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)**. *Annals of the rheumatic diseases* 2006, **65**(10):1312-1324.

14. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G: **British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.** *Rheumatology (Oxford, England)* 2007, **46**(8):1372-1374.
15. Dynamed: **Gout management - treatment of acute attack.** In. Ipswich, MA: EBSCO Information Services; 2015.
16. Jarupongprapa S, Ussavasodhi P, Katchamart W: **Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.** *Journal of gastroenterology* 2013, **48**(7):830-838.
17. Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, Trifiro G, Goldstein JL, Hernandez-Diaz S, Kuipers EJ *et al*: **Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?** *Alimentary pharmacology & therapeutics* 2013, **38**(2):178-189.
18. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J: **Prevention of NSAID-induced gastroduodenal ulcers.** *The Cochrane database of systematic reviews* 2002(4):CD002296.
19. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N *et al*: **Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.** *Journal of psychopharmacology* 2014, **28**(5):403-439.
20. NICE: **Non-steroidal anti-inflammatory drugs.** 2015.
21. Wortmann RL, Macdonald PA, Hunt B, Jackson RL: **Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.** *Clinical therapeutics* 2010, **32**(14):2386-2397.
22. Rees F, Jenkins W, Doherty M: **Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.** *Annals of the rheumatic diseases* 2013, **72**(6):826-830.
23. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewe RB: **Non-steroidal anti-inflammatory drugs for acute gout.** *The Cochrane database of systematic reviews* 2014(9):CD010120.
24. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D: **Colchicine for acute gout.** *The Cochrane database of systematic reviews* 2014(8):CD006190.
25. Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L: **Interleukin-1 inhibitors for acute gout.** *The Cochrane database of systematic reviews* 2014(9):CD009993.
26. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH: **Systemic corticosteroids for acute gout.** *The Cochrane database of systematic reviews* 2008(2):CD005521.
27. Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R: **Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.** *Annals of internal medicine* 2017, **166**(1):37-51.

28. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M: **Does colchicine work? The results of the first controlled study in acute gout.** *Australian and New Zealand journal of medicine* 1987, **17**(3):301-304.
29. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW: **High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.** *Arthritis and rheumatism* 2010, **62**(4):1060-1068.
30. de la Torre G: **A comparative, double-blind parallel study with tenoxicam vs placebo in acute gouty arthritis.** *Invest Med Int* 1987, **14**:92.
31. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C: **Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.** *Lancet (London, England)* 2008, **371**(9627):1854-1860.
32. Man CY, Cheung IT, Cameron PA, Rainer TH: **Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.** *Annals of emergency medicine* 2007, **49**(5):670-677.
33. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH, Graham CA: **Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.** *Annals of internal medicine* 2016, **164**(7):464-471.
34. Neogi T: **Gout.** *Annals of internal medicine* 2016, **165**(1):ITC1-ITC16.
35. Dalbeth N, Merriman TR, Stamp LK: **Gout.** *Lancet (London, England)* 2016, **388**(10055):2039-2052.
36. Schlesinger N, Schumacher R, Catton M, Maxwell L: **Colchicine for acute gout.** *The Cochrane database of systematic reviews* 2006(4):CD006190.
37. Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH: **Update on colchicine, 2017.** *Rheumatology* 2018, **57**(suppl_1):i4-i11.
38. Sutaria S, Katbamna R, Underwood M: **Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.** *Rheumatology (Oxford, England)* 2006, **45**(11):1422-1431.
39. Garcia de la Torre I: **Double-blind parallel study comparing tenoxicam and placebo in acute gouty arthritis.** *Invet Med Int* 1987, **14**:92-97.
40. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA *et al*: **Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.** *Arthritis and rheumatism* 2004, **50**(2):598-606.
41. Schumacher HR, Jr., Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J: **Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.** *BMJ (Clinical research ed)* 2002, **324**(7352):1488-1492.

42. Maccagno A, Di Giorgio E, Romanowicz A: **Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.** *Current medical research and opinion* 1991, **12**(7):423-429.
43. Lederman R: **A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout.** *Adv Ther* 1990, **7**:344-354.
44. Altman RD, Honig S, Levin JM, Lightfoot RW: **Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study.** *The Journal of rheumatology* 1988, **15**(9):1422-1426.
45. Lomen PL, Turner LF, Lamborn KR, Winblad MA, Sack RL, Brinn EL: **Flurbiprofen in the treatment of acute gout. A comparison with indomethacin.** *The American journal of medicine* 1986, **80**(3A):134-139.
46. Li T, Chen SL, Dai Q, Han XH, Li ZG, Wu DH, Zhang X, Gu JR, Yang NP, Sun LY *et al*: **Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.** *Chinese medical journal* 2013, **126**(10):1867-1871.
47. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C: **Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.** *The Journal of rheumatology* 2012, **39**(9):1859-1866.
48. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: **Viscosupplementation for the treatment of osteoarthritis of the knee.** *The Cochrane database of systematic reviews* 2006(2):CD005321.
49. Rutjes AW, Juni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S: **Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.** *Annals of internal medicine* 2012, **157**(3):180-191.
50. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE: **Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.** *Annals of internal medicine* 2015, **162**(1):46-54.
51. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: **Intraarticular corticosteroid for treatment of osteoarthritis of the knee.** *The Cochrane database of systematic reviews* 2006(2):CD005328.
52. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P: **American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.** *Arthritis care & research* 2012, **64**(4):465-474.
53. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H *et al*: **OARSI guidelines for the non-surgical management of knee osteoarthritis.** *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2014, **22**(3):363-388.
54. Zhang YK, Yang H, Zhang JY, Song LJ, Fan YC: **Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout.** *International journal of clinical practice* 2014, **68**(5):633-638.
55. Badlissi F: **Gout.** In: *BMJ Best Practice.* 2018.

56. Kapur S, Kraag G: **Musculoskeletal Disorders: Gout and Hyperuricemia**. In: *Therapeutics*. Edited by Jean G. Ottawa (ON): Canadian Pharmacists Association; 2015.
57. Dumont Z, Crawley A, Jensen B, Regier L: **GOUT: Overview and Pharmacology**. In: *RxFiles drug comparison charts*. Edited by Edition t. Saskatoon, SK: Saskatoon Health Region; 2017.
58. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK: **Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions**. *Annals of the rheumatic diseases* 2012, **71**(11):1839-1848.
59. So A, De Smedt T, Revaz S, Tschopp J: **A pilot study of IL-1 inhibition by anakinra in acute gout**. *Arthritis research & therapy* 2007, **9**(2):R28.
60. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L: **Anakinra's efficacy is variable in refractory gout: report of ten cases**. *Semin Arthritis Rheum* 2010, **40**(3):210-214.
61. Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, Palazzo E, Meyer O, Richette P, Bardin T *et al*: **Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases**. *Arthritis research & therapy* 2013, **15**(5):R123.
62. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC: **Treatment of acute gouty arthritis in complex hospitalized patients with anakinra**. *Arthritis care & research* 2013, **65**(8):1381-1384.
63. Terkeltaub R, Sundry JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A: **The interleukin 1 inhibitor riloncept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study**. *Annals of the rheumatic diseases* 2009, **68**(10):1613-1617.
64. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP: **Riloncept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator**. *Arthritis research & therapy* 2013, **15**(1):R25.
65. Schlesinger N: **Canakinumab in gout**. *Expert opinion on biological therapy* 2012, **12**(9):1265-1275.
66. Sandoz Canada Inc: **Sandoz Colchicine**. In: *CA Product Monograph*. Boucherville, QC; 2017.
67. Odan Laboratories Ltd.: **Colchicine**. In: *CA Product Monograph*. Pointe-Claire, QC; 2016.
68. Takeda: **Colcrys (colchicine)**. In: *US Monograph*. 01/2018 edn. Deerfield, IL: Takeda; 2018.
69. Association CP: **Colchicine CPhA Monograph**. In: *CPS*. Ottawa, Ontario: Canadian Pharmacists Association; 2014.
70. Pfizer Canada Inc: **Solu-Medrol (methylprednisolone sodium succinate)**. In: *CA Product Monograph*. Kirkland, Quebec; 2021.
71. Cardinal Health: **Solu-Medrol (methylprednisolone sodium succinate)**. In: *US Product Monograph*. Dublin, OH; 2020.
72. **Adult Drug Book**. In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.

73. AA Pharma Inc: **Winpred (prednisone)**. In: *CA Product Monograph*. Vaughan, Ontario; 2018.
74. Horizon Pharma Inc: **Rayos (prednisone)**. In: *US Product Monograph*. Lake Forest, IL; 2019.
75. Badlissi F: **Gout**. *BMJ Best Practice* 2020.
76. Pfizer Canada Inc.: **DEPO-MEDROL**. In: *CA Product Monograph*. Kirkland, Quebec: Pfizer Canada Inc.; 2021.
77. Pfizer: **Depo-Medrol**. In: *US Product Monograph*. Dec 2020 edn. New York, NY USA: Pfizer 2020.
78. Inc S: **Triamcinolone Acetonide Injectable Suspension USP**. In: *CA Product Monograph*. Oakville, On: SteriMax; 2020.
79. E.R. Squibb & Sons L: **Kenalog-40 Injection**. In: *US Product Monograph*. Princeton, NJ: Bristol-Myers Squibb; 2019.
80. Inc A: **Apo-Celecoxib**. In: *CA Product Monograph*. Toronto, ON; 2020.
81. Pfizer: **Celebrex (celecoxib)**. In: *US Product Monograph*. New York, New York; 2020.
82. Association CP: **Nonsteroidal Anti-inflammatory Drugs (NSAIDs) [CPhA Monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
83. Lee M, Jensen B, Regier L: **NSAIDS & COXIB ANALGESICS: Drug Comparison Chart**. In: *RxFiles drug comparison charts*. Edited by Edition t. Saskatoon, SK: Saskatoon Health Region; 2017.
84. Limited TC: **Teva-Diclofenac-K (diclofenac potassium)**. In: *CA Product Monograph*. Toronto, ON; 2021.
85. Inc A: **Diclofenac Sodium Slow Release Tablets**. In: *CA Product Monograph*. Toronto, ON; 2020.
86. Actavis Elizabeth LLC: **Diclofenac sodium**. In: *US Product Monograph*. Elizabeth, New Jersey; 2020.
87. Pharmaceuticals T: **Cambia**. In: *Product Monograph*. London, ON; 2015.
88. Apotex Inc: **Apo-Ibuprofen**. In: *CA Product Monograph*. Toronto, Ontario; 2020.
89. Pharmaceuticals A: **Ibuprofen**. In: *US Product Monograph*. January 2021 edn. Bridgewater, NJ: Amneal Pharmaceuticals; 2021.
90. Pfizer Consumer Healthcare: **Advil**. In: *Product Monograph*. Mississauga, Ontario: Pfizer Consumer Healthcare; 2017.
91. Aphen: **Ibuprofen**. In: *US Product Monograph*. October, 2017 edn. Cookeville, TN USA: Aphen Pharma Solutions; 2017.
92. Apotex Inc: **Apo-Ibuprofen**. In: *CA Product Monograph*. Toronto, Ontario; 2017.
93. Mint Pharmaceuticals Inc: **Mint-indomethacin**. In: *CA Product Monograph*. Mississauga, ON; 2017.
94. Inc GP: **Indomethacin**. In: *US Product Monograph*. Mahwah, NJ; 2021.
95. Teva Canada Limited: **Teva-meloxicam**. In: *CA Product Monograph*. Toronto, ON; 2020.
96. Inc. RPH: **Meloxicam**. In: *US Product Monograph*. East Brunswick, NJ; 2021.
97. Boehringer Ingelheim Pharmaceuticals: **Mobic (meloxicam)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
98. Health S: **Naproxen**. In: *Product Monograph*. Brampton, ON; 2017.

99. Atnahs: **Naprosyn (naproxen)**. In: *US Monograph*. Aug 2016 edn. Basildon, Essex, SS14 3FR, United Kingdom: Atnahs Pharma; 2016.
100. Canton Laboratories LLC: **Naprosyn (naproxen)**. In: *US Product Monograph*. Alpharetta, GA; 2019.
101. Bayer Inc. Consumer Care: **Aleve**. In: *Product Monograph*. Mississauga: Bayer Inc. Consumer Care; 2017.
102. Genentech: **Naproxen Sodium**. In: *US Product Monograph*. October 2010 edn. South San Francisco, CA: Genentech USA, Inc.; 2010.
103. Atnahs Pharma UK Limited: **Anaprox**. In: *Product Monograph*. Basildon, Essex: Atnahs Pharma UK Limited; 2015.
104. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA: **Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs**. *Clin Pharmacol Ther* 2006, **79**(5):407-418.
105. Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW *et al*: **Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite**. *Arch Pharm Res* 2017, **40**(3):382-390.
106. Liu R, Gong C, Tao L, Yang W, Zheng X, Ma P, Ding L: **Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects**. *Eur J Pharm Sci* 2015, **79**:13-19.
107. Murto K, Lamontagne C, McFaul C, MacCormick J, Ramakko KA, Aglipay M, Rosen D, Vaillancourt R: **Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study**. *Can J Anaesth* 2015, **62**(7):785-797.
108. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F *et al*: **Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms**. *Gastroenterology* 2007, **133**(2):465-471.
109. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA: **Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use**. *Br J Pharmacol* 2004, **141**(2):205-208.
110. Prieto-Perez R, Ochoa D, Cabaleiro T, Roman M, Sanchez-Rojas SD, Talegon M, Abad-Santos F: **Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib**. *J Clin Pharmacol* 2013, **53**(12):1261-1267.
111. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J: **Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites**. *Pharmacogenetics* 2003, **13**(8):473-480.
112. Figueiras A, Estany-Gestal A, Aguirre C, Ruiz B, Vidal X, Carvajal A, Salado I, Salgado-Barreira A, Rodella L, Moretti U *et al*: **CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study**. *Pharmacogenet Genomics* 2016, **26**(2):66-73.
113. Aithal GP, Day CP, Leathart JB, Daly AK: **Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis**. *Pharmacogenetics* 2000, **10**(6):511-518.

114. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: **Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.** *Br J Clin Pharmacol* 2003, **55**(1):51-61.
115. Agundez JA, Garcia-Martin E, Martinez C: **Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?** *Expert Opin Drug Metab Toxicol* 2009, **5**(6):607-620.